Papillomavirus

Mel-Mont Medical announces the validation of its patented self-sampling technology, Mía by XytoTest®, for molecular screening using HPV-DNA and 7-Type mRNA E6/E7.

Retrieved on: 
Wednesday, August 4, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Gynaecological cancer, Sexually transmitted diseases and infections, Vaccines, Human papillomavirus infection, Cervical cancer, HPV vaccine, HspE7

KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ -- Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling.

Key Points: 
  • "Current estimates indicate that every year 569,847 women are diagnosed with cervical cancer, and 311,365 die from the disease.
  • Cervical cancer ranks as the third most frequent cancer among women in the world," according to Globocan information center on HPV and cancer.
  • The uniqueness of Ma by XytoTest empowers sexually active women to further their self-care opportunities and pre-screen for HPV-caused cancers.
  • PreTect AS, a fully ISO 13485:2016, CE/IVD certified, and FDA registered mRNA manufacturing facility based in Klokkarstua, Norway, is a wholly-owned subsidiary of Mel-Mont Medical, Inc.

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Clinical trials, Health, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Papillomavirus, Vaccines, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Clinical trial, HspE7

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

ISA Pharmaceuticals, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Health, Medicine, Clinical research, Design of experiments, Human papillomavirus infection, Papillomavirus, Clinical trial

The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.

Key Points: 
  • The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.
  • The project starts in August 2021 and the clinical phase is expected to begin in 2022.
  • It will provide an insight into which dose of ISA104 is safe, tolerable and potentially effective in chronic HBV patients.
  • It will be ISA's next program to go into clinical development, with its lead program ISA101b in late-stage clinical trials for human papillomavirus type 16 (HPV16) induced cancers.

SA Pharmaceuticals, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Health, Medicine, Clinical research, Design of experiments, Human papillomavirus infection, Papillomavirus, Clinical trial

The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.

Key Points: 
  • The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.
  • The project starts in August 2021 and the clinical phase is expected to begin in 2022.
  • It will provide an insight into which dose of ISA104 is safe, tolerable and potentially effective in chronic HBV patients.
  • It will be ISA's next program to go into clinical development, with its lead program ISA101b in late-stage clinical trials for human papillomavirus type 16 (HPV16) induced cancers.

United States Vaccine Market Report 2021: Focus on COVID-19, Flu, Adult, Children, Adolescent and Travel Vaccines - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Papillomavirus, Clinical medicine, Medicine, Vaccination, Infectious causes of cancer, Vaccine, Virology, Human papillomavirus infection, T

Global HPV Market Worth $3.3 Billion; Meningococcal Vaccine Market $1.9 Billion

Key Points: 

Global HPV Market Worth $3.3 Billion; Meningococcal Vaccine Market $1.9 Billion
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005307/en/

Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical devices, Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Vaccines, Cancer vaccines, Gynaecological cancer, Human papillomavirus infection, Papillomaviridae, Cervical cancer, Papilloma

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • HPV infection is the major cause of cervical cancers, with almost all cases (99%) being caused by HPV infection.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).

North America HPV Testing and Pap Test Market Potential, Industry Analysis and Forecast Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Women, Other Health, Consumer, Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Pap test, Cervical cancer, HPV vaccine, Cervical screening

The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, the growing number of cervical cancer cases may surge the demand for HPV testing and PAP tests, boosting the market growth.
  • Thus, the growing cases of cervical cancer across the North American region are expected to boost the demand for HPV testing and Pap test market over the forthcoming years.
  • The US market dominated the North America HPV Testing Market by Country 2020, thereby, achieving a market value of $844.5 million by 2027.

Global HPV Testing and Pap Test Market Analysis Report and Forecast, 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021
Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Pap test, PAP

The "Global HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global HPV Testing and Pap Test Market size is expected to reach $7.1 billion by 2027, rising at a market growth of 33.5% CAGR during the forecast period.
  • It is suggested that a woman should undergo a Pap test every 3 years starting from the age of 21.
  • Therefore, the outbreak of COVID-19 pandemic has adversely affected the HPV testing and Pap test market.

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Cancer, Clinical medicine, Medicine, Infectious causes of cancer, Otorhinolaryngology, Papillomavirus, Cancer immunotherapy, Head and neck cancer, Human papillomavirus infection, Immunotherapy, Squamous cell carcinoma, HPV-positive oropharyngeal cancer

THE FIRST UK PATIENT OF THE TRIAL EVALUATING THIS INDIVIDUALIZED CANCER IMMUNOTHERAPY HAS BEEN INCLUDED IN LIVERPOOL, UK, in a trial enrolling patients with squamous cell carcinoma of the head and neck.

Key Points: 
  • THE FIRST UK PATIENT OF THE TRIAL EVALUATING THIS INDIVIDUALIZED CANCER IMMUNOTHERAPY HAS BEEN INCLUDED IN LIVERPOOL, UK, in a trial enrolling patients with squamous cell carcinoma of the head and neck.
  • If successful, this technique could be a potentially game-changing development in the treatment of advanced head and neck cancers.
  • Head and neck cancers are particularly complex to treat if they spread and cannot then be completely removed surgically.
  • In a first Phase I trial, TG4050 is being administered to patients with HPV-negative head and neck cancer ( NCT04183166 ).

Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers

Retrieved on: 
Thursday, June 24, 2021
Oncology, Health, Stem cells, Genetics, Other Health, Clinical trials, Biotechnology, Cancer, Clinical medicine, Health, Infectious causes of cancer, Papillomavirus, Otorhinolaryngology, Breakthrough therapy, Orphan drugs, Human papillomavirus infection, Avelumab, Head and neck cancer, Anal cancer

The randomized Phase II trial is focusing on patients with recurrent or metastatic HPV16-positive anogenital cancer, including cervical, vulvar, vaginal, penile, and anal cancer, without liver metastases.

Key Points: 
  • The randomized Phase II trial is focusing on patients with recurrent or metastatic HPV16-positive anogenital cancer, including cervical, vulvar, vaginal, penile, and anal cancer, without liver metastases.
  • In the Phase Ib/II part of the study, very encouraging clinical outcome was observed in patients without liver metastases [1,2].
  • Patients will be randomized to either receive the combination regimen of the therapeutic vaccine TG4001 and avelumab or avelumab alone.
  • The combination of TG4001 and avelumab demonstrated anti-tumor activity (23.5% ORR) in patients with previously treated recurrent and/or metastatic HPV-related cancers (including patients with oropharyngeal cancers and anogenital cancers).